CIK 0001868279 · Non-accelerated filer<br>Emerging growth company
ArriVent BioPharma, Inc.
Sign in to watch- Ticker
- AVBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 240-780-6356
- Business address
- 18 CAMPUS BLVD., SUITE 100, NEWTOWN SQUARE, PA, 19073-3269
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-30 | ORBIMED ADVISORS LLC Director | Conversion · Series A Preferred Stock | −821,827 | 0 | ||
| 2024-01-30 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −469,615 | 0 | ||
| 2024-01-30 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −469,615 | 0 | ||
| 2024-01-30 | GORDON CARL L Director | Conversion | +821,827 | 821,827 | ||
| 2024-01-30 | GORDON CARL L Director | Conversion | +821,827 | 821,827 | ||
| 2024-01-30 | GORDON CARL L Director | Conversion | +469,615 | 1,291,442 | ||
| 2024-01-30 | GORDON CARL L Director | Conversion | +469,615 | 1,291,442 | ||
| 2024-01-30 | GORDON CARL L Director | Purchase | +222,222 | $18.00 | $4.0M | 1,513,664 |
| 2024-01-30 | GORDON CARL L Director | Purchase | +222,222 | $18.00 | $4.0M | 1,513,664 |
| 2024-01-30 | GORDON CARL L Director | Conversion · Series A Preferred Stock | −821,827 | 0 | ||
| 2024-01-30 | GORDON CARL L Director | Conversion · Series A Preferred Stock | −821,827 | 0 | ||
| 2024-01-30 | GORDON CARL L Director | Conversion · Series B Preferred Stock | −469,615 | 0 | ||
| 2024-01-30 | GORDON CARL L Director | Conversion · Series B Preferred Stock | −469,615 | 0 | ||
| 2024-01-30 | HEALY JAMES Director | Conversion | +1,252,308 | 1,252,308 | ||
| 2024-01-30 | HEALY JAMES Director | Purchase | +444,444 | $18.00 | $8.0M | 1,696,752 |
| 2024-01-30 | HEALY JAMES Director | Conversion · Series B Preferred Stock | −1,252,308 | 0 | ||
| 2024-01-25 | Nolet Chris Director | Grant or award · Stock Option (right to buy) | +17,884 | 17,884 | ||
| 2024-01-25 | Jallal Bahija Director | Grant or award · Stock Option (right to buy) | +17,884 | 17,884 |
Page 4 of 4 · 78 trades